DMAA
DMAA
NASDAQ · N/A

Drugs Made In America Acquis

$10.51
+0.01 (+0.10%)
Financial Highlights (FY 2025)
Revenue
219.69M
Net Income
25.03M
Gross Margin
29.5%
Profit Margin
11.4%
Rev Growth
-5.7%
D/E Ratio
0.87
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 29.5% 29.5% 29.5%
Operating Margin 12.8% 13.1% 12.1%
Profit Margin 11.4% 11.4% 10.0%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 219.69M 205.61M 216.54M
Gross Profit 64.87M 60.71M 63.94M
Operating Income 28.19M 26.95M 26.25M
Net Income 25.03M 23.39M 21.58M
Gross Margin 29.5% 29.5% 29.5%
Operating Margin 12.8% 13.1% 12.1%
Profit Margin 11.4% 11.4% 10.0%
Rev Growth -5.7% -2.0% +21.2%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 120.38M 114.41M 149.81M
Total Equity 137.89M 132.67M 131.31M
D/E Ratio 0.87 0.86 1.14
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 37.03M 38.19M 42.37M
Free Cash Flow 19.51M 14.22M 14.32M